These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 14634213)

  • 21. A post-ubiquitination role for MDM2 and hHR23A in the p53 degradation pathway.
    Brignone C; Bradley KE; Kisselev AF; Grossman SR
    Oncogene; 2004 May; 23(23):4121-9. PubMed ID: 15064742
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interaction of human NAD(P)H:quinone oxidoreductase 1 (NQO1) with the tumor suppressor protein p53 in cells and cell-free systems.
    Anwar A; Dehn D; Siegel D; Kepa JK; Tang LJ; Pietenpol JA; Ross D
    J Biol Chem; 2003 Mar; 278(12):10368-73. PubMed ID: 12529318
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacological inhibitors of NAD(P)H quinone oxidoreductase, NQO1: structure/activity relationships and functional activity in tumour cells.
    Nolan KA; Scott KA; Barnes J; Doncaster J; Whitehead RC; Stratford IJ
    Biochem Pharmacol; 2010 Oct; 80(7):977-81. PubMed ID: 20599803
    [TBL] [Abstract][Full Text] [Related]  

  • 24. MDM2 promotes ubiquitination and degradation of MDMX.
    Pan Y; Chen J
    Mol Cell Biol; 2003 Aug; 23(15):5113-21. PubMed ID: 12860999
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interaction of the molecular chaperone Hsp70 with human NAD(P)H:quinone oxidoreductase 1.
    Anwar A; Siegel D; Kepa JK; Ross D
    J Biol Chem; 2002 Apr; 277(16):14060-7. PubMed ID: 11821413
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rapid polyubiquitination and proteasomal degradation of a mutant form of NAD(P)H:quinone oxidoreductase 1.
    Siegel D; Anwar A; Winski SL; Kepa JK; Zolman KL; Ross D
    Mol Pharmacol; 2001 Feb; 59(2):263-8. PubMed ID: 11160862
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The ubiquitin ligase COP1 is a critical negative regulator of p53.
    Dornan D; Wertz I; Shimizu H; Arnott D; Frantz GD; Dowd P; O'Rourke K; Koeppen H; Dixit VM
    Nature; 2004 May; 429(6987):86-92. PubMed ID: 15103385
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The MDM2-p53 interaction.
    Moll UM; Petrenko O
    Mol Cancer Res; 2003 Dec; 1(14):1001-8. PubMed ID: 14707283
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regulation of p53 by Mdm2: fate is in the numbers.
    Shmueli A; Oren M
    Mol Cell; 2004 Jan; 13(1):4-5. PubMed ID: 14731389
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Functional p53 chimeras containing the Epstein-Barr virus Gly-Ala repeat are protected from Mdm2- and HPV-E6-induced proteolysis.
    Heessen S; Leonchiks A; Issaeva N; Sharipo A; Selivanova G; Masucci MG; Dantuma NP
    Proc Natl Acad Sci U S A; 2002 Feb; 99(3):1532-7. PubMed ID: 11805282
    [TBL] [Abstract][Full Text] [Related]  

  • 31. MDM2 binding induces a conformational change in p53 that is opposed by heat-shock protein 90 and precedes p53 proteasomal degradation.
    Sasaki M; Nie L; Maki CG
    J Biol Chem; 2007 May; 282(19):14626-34. PubMed ID: 17363365
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Topors functions as an E3 ubiquitin ligase with specific E2 enzymes and ubiquitinates p53.
    Rajendra R; Malegaonkar D; Pungaliya P; Marshall H; Rasheed Z; Brownell J; Liu LF; Lutzker S; Saleem A; Rubin EH
    J Biol Chem; 2004 Aug; 279(35):36440-4. PubMed ID: 15247280
    [TBL] [Abstract][Full Text] [Related]  

  • 33. NAD(P)H quinone oxidoreductase (NQO1): an enzyme which needs just enough mobility, in just the right places.
    Pey AL; Megarity CF; Timson DJ
    Biosci Rep; 2019 Jan; 39(1):. PubMed ID: 30518535
    [TBL] [Abstract][Full Text] [Related]  

  • 34. mdm2 and bax, downstream mediators of the p53 response, are degraded by the ubiquitin-proteasome pathway.
    Chang YC; Lee YS; Tejima T; Tanaka K; Omura S; Heintz NH; Mitsui Y; Magae J
    Cell Growth Differ; 1998 Jan; 9(1):79-84. PubMed ID: 9438391
    [TBL] [Abstract][Full Text] [Related]  

  • 35. N-terminal polyubiquitination and degradation of the Arf tumor suppressor.
    Kuo ML; den Besten W; Bertwistle D; Roussel MF; Sherr CJ
    Genes Dev; 2004 Aug; 18(15):1862-74. PubMed ID: 15289458
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hypophosphorylation of Mdm2 augments p53 stability.
    Blattner C; Hay T; Meek DW; Lane DP
    Mol Cell Biol; 2002 Sep; 22(17):6170-82. PubMed ID: 12167711
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cocompartmentalization of p53 and Mdm2 is a major determinant for Mdm2-mediated degradation of p53.
    Xirodimas DP; Stephen CW; Lane DP
    Exp Cell Res; 2001 Oct; 270(1):66-77. PubMed ID: 11597128
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cytoplasmically "sequestered" wild type p53 protein is resistant to Mdm2-mediated degradation.
    Zaika A; Marchenko N; Moll UM
    J Biol Chem; 1999 Sep; 274(39):27474-80. PubMed ID: 10488081
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Akt enhances Mdm2-mediated ubiquitination and degradation of p53.
    Ogawara Y; Kishishita S; Obata T; Isazawa Y; Suzuki T; Tanaka K; Masuyama N; Gotoh Y
    J Biol Chem; 2002 Jun; 277(24):21843-50. PubMed ID: 11923280
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Monoubiquitination: the signal for p53 nuclear export?
    Brooks CL; Li M; Gu W
    Cell Cycle; 2004 Apr; 3(4):436-8. PubMed ID: 14976431
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.